Investigational drug · Phase 3
NB003
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for GIST - Gastrointestinal Stromal Tumor, Advanced.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "NB003"
First trial start
2026
May 11, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NB003", any sponsor or status.
Conditions studied
As listed on its trial records.
- GIST - Gastrointestinal Stromal Tumor
- Advanced
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "NB003" as an intervention, largest first.
- First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorsActive, not recruiting
IDRX, Inc., a wholly owned subsidiary of GSK, LLCIndustry
NCT05489237 · 276 participants · Start Aug 3, 2022 · Primary completion Mar 10, 2027
Drug: IDRX-42 · For: Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumor (GIST); Digestive System Disease and 2 more
Sites: Miami, Florida; Chicago, Illinois; Boston, Massachusetts · 31 sites in all
Ningbo Newbay Technology Development Co., LtdIndustry
NCT04936178 · 258 participants · Start Aug 6, 2021 · Primary completion Aug 1, 2025
Drug: NB003 tablets · For: Advanced Solid Tumor
Sites: Stanford, California; Jacksonville, Florida; Boston, Massachusetts · 32 sites in all
- Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)Pivotal-lookingRecruiting
Ningbo Newbay Technology Development Co., LtdIndustry
NCT07379047 · 255 participants (planned) · Start May 11, 2026 · Primary completion Aug 1, 2028
Drug: NB003; regorafenib · For: GIST - Gastrointestinal Stromal Tumor; Advanced
Sites: Hefei, China; Beijing, China; Chongqing, China · 36 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.
Cicala CM, Olivares-Rivas I, Aguirre-Carrillo JA, et al. · Expert Opin Investig Drugs 2024
- Antibiotic resistance to Propionobacterium acnes: worldwide scenario, diagnosis and management.
Sardana K, Gupta T, Garg VK, et al. · Expert Rev Anti Infect Ther 2015
- In vitro antibacterial activity of NB-003 against Propionibacterium acnes.
Pannu J, McCarthy A, Martin A, et al. · Antimicrob Agents Chemother 2011
- Interscience Conference on Antimicrobial Agents and Chemotherapy - 50th Annual Meeting - Research on Promising New Agents: Part 2.
Walker K · IDrugs 2010
Also in development for GIST - Gastrointestinal Stromal Tumor
- KQB198Phase 21 trial
Kumquat Biosciences Inc. · GIST - Gastrointestinal Stromal Tumor, GIST, GIST Metastatic Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.